Pandemic spurs 'country level action' on PGIM Jennison Emerging Markets

Delta variant not impacted Indian market

clock • 2 min read
Sara Moreno of PGIM
Image:

Sara Moreno of PGIM

The Covid pandemic led Sara Moreno, co-manager of the $355m PGIM Jennison Emerging Markets Equity fund, to take action at a country level “for the first time in the history of the fund”, she revealed to Investment Week.

Moreno explained that normally she and her co-managers focus on building the portfolio one stock at a time and tend not to take positions on a specific country. However, towards the beginning of the pandemic, while other countries' equity markets were correcting, India had not. 

"We talked to experts and India was in trouble, potentially. We took, for the first time in our history, very swift action looking at the country level, which we do not typically do," she said. 

The managers took their 15%-16% allocation to India down to near zero, maintaining just one holding. 

HFEL: Asia Pacific profits prove resilient during Covid-19 recession

Then, in the autumn, the managers decided to go back into India as the country "had done a good job of managing the virus". By the end of 2020, they were almost back to their previous weight in India and have since topped it up further. 

In 2020, the fund returned 72.4% compared to its benchmark, the MSCI Emerging Markets index, which returned 54.1%, according to Morningstar. 

Despite the impact of the Delta variant, which has caused India challenges in 2021, market reaction in the country has been limited, according to Moreno.  

Moreno remains bullish about the nation and the fund had 20.4% in India by the end of May, according to its latest factsheet. 

The significant allocation to the country is in part because the manager views it as "the last true emerging market in emerging markets". 

Meanwhile, the managers have taken weight off of China as a result of "increasing policy risk" and because the opportunities there are more "mature". 

In November 2019, the fund had 46.9% allocated to China but this had dropped to 34.8% at the end of May, according to the fund's factsheets. 

One stock no longer in the portfolio is Alibaba, which the managers had held since IPO. 

During the pandemic, smaller digital platforms in China "accelerated" and while Moreno expects Alibaba to "continue at a good clip", the company would have to invest more to get there.

However, the managers are still "aggressively overweight" in healthcare, which makes up 14.3% of the portfolio, and are particularly interested in Chinese healthcare companies. 

The country has historically only spent 5% of GDP on healthcare compared to 17% for the US. 

"If you want to move from a low-income, middle-income country to a high-income one, you need to invest more in healthcare and China is doing that," Moreno said. 

More recently the Chinese have invested double digits in healthcare and pharmaceuticals which has "unleashed a plethora of opportunities", she added.

More on Emerging markets

Dmytro Spilka of Solvid

Fuelling the LSE's revival: Could a Huel IPO turn around the London Stock Exchange's fortunes in 2022?

Other possible IPOs include EG Group, Monzo and Starling Bank

Dmytro Spilka
clock 13 January 2022 • 4 min read
The new fund will be managed by Hong Kong-based Wenli Zheng

T. Rowe Price launches China ex-mega cap equity fund

Avoid 100 largest stocks

Nafeesa Zaman
clock 12 January 2022 • 2 min read
Investment Week Podcast

Podcast: 2022 outlook on emerging markets

Emerging market outlook

Alex Rolandi
clock 12 January 2022 • 1 min read
Trustpilot